Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PERIOGARD vs ACETAMINOPHEN AND CODEINE PHOSPHATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Chlorhexidine gluconate is a cationic bisbiguanide that disrupts microbial cell membrane integrity, leading to leakage of intracellular contents and cell death. It exhibits broad-spectrum antimicrobial activity against gram-positive and gram-negative bacteria, fungi, and viruses.
Acetaminophen: centrally acting analgesic and antipyretic, possibly via inhibition of cyclooxygenase (COX) and modulation of cannabinoid receptors. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.
Treatment of gingivitis characterized by redness, swelling, and bleeding, including bleeding on probing,Off-label: Oral mucositis, peri-implantitis, dental caries prevention, reduction of oral bacterial load in immunocompromised patients
Mild to moderate pain,Pain accompanied by fever
15 m L chlorhexidine gluconate 0.12% oral rinse twice daily for 30 seconds and expectorate.
One or two tablets (acetaminophen 300 mg/codeine 30 mg per tablet) orally every 4-6 hours as needed for pain; maximum 12 tablets daily.
6-7 hours (prolonged in renal impairment; no dosage adjustment for topical oral use).
Acetaminophen: 2–3 hours (prolonged in hepatic impairment). Codeine: 2.5–3.5 hours; metabolites: morphine 1.5–2.5 hours, codeine-6-glucuronide 3–4 hours. Clinical context: dosing interval every 4–6 hours.
Chlorhexidine is not significantly absorbed systemically following oral topical application; minimal metabolism occurs in the liver, with primary excretion via feces.
Acetaminophen: primarily glucuronidation and sulfation in liver; minor CYP450 (CYP2E1) to toxic NAPQI. Codeine: CYP2D6 to morphine; CYP3A4 to norcodeine; glucuronidation.
Primarily renal (70-80% unchanged via glomerular filtration); minor biliary/fecal (20-30%).
Acetaminophen: renal elimination of conjugated metabolites (glucuronide 60%, sulfate 30%, cysteine/mercapturate <5%), less than 5% unchanged. Codeine: renal elimination of codeine (5–15%), morphine (5–10%), norcodeine (10–20%), and conjugates; 90% excreted in urine within 24 hours.
Very low (10-18%), primarily to serum proteins (albumin).
Acetaminophen: 10–25% (albumin). Codeine: 7–25% (primarily albumin).
0.2-0.3 L/kg (minimal systemic distribution, consistent with poor absorption from oral topical use).
Acetaminophen: 0.9 L/kg. Codeine: 3–6 L/kg (extensive tissue distribution).
Topical oral (mouthwash): <1% (minimal systemic absorption).
Oral: acetaminophen 88% (variable first-pass); codeine 50–60% (first-pass metabolism to morphine, norcodeine, and conjugates).
No dose adjustment required; negligible systemic absorption.
GFR 30-50 m L/min: administer every 6 hours; GFR 10-29 m L/min: administer every 8 hours; GFR <10 m L/min: administer every 12 hours; hemodialysis: not recommended.
No dose adjustment required; negligible hepatic metabolism.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and extend interval to every 8 hours; Child-Pugh C: contraindicated.
Not recommended for children under 18 years due to safety and efficacy data lacking.
For children ≥12 years: acetaminophen 10-15 mg/kg/dose and codeine 0.5-1 mg/kg/dose orally every 4-6 hours; maximum acetaminophen 75 mg/kg/day, codeine 6 mg/kg/day. For children <12 years: not recommended due to codeine safety concerns.
No specific dose adjustment; use with caution if dysphagia or aspiration risk present.
Start with lowest effective dose; acetaminophen component maximum 3 g/day; consider reduced codeine dose (e.g., 15 mg) due to increased sensitivity and risk of respiratory depression; extend dosing interval to every 6-8 hours.
No FDA black box warning.
Risk of medication errors: confusion between milligram and milliliter doses, and between codeine and acetaminophen components. Contraindicated for postoperative pain management in children following tonsillectomy/adenoidectomy due to risk of respiratory depression and death.
Avoid contact with eyes, ears, and mucous membranes; may cause staining of teeth, tongue, and dental restorations; hypoesthesia of tongue may occur; anaphylaxis and serious allergic reactions reported; use with caution in patients with known hypersensitivity; not for use in children under 6 years.
Hepatotoxicity (acetaminophen overdose); respiratory depression; drug dependence; ultra-rapid metabolizers of codeine (CYP2D6) leading to morphine toxicity; concomitant CNS depressants; use in pediatric patients; avoid alcohol.
Hypersensitivity to chlorhexidine gluconate or any component of the formulation
Hypersensitivity to acetaminophen or codeine; severe respiratory depression; acute or severe asthma; paralytic ileus; post-operative pain management in children after tonsillectomy/adenoidectomy; breastfeeding (in ultra-rapid metabolizers); concomitant MAOIs.
Avoid food, beverages, and other oral care products (e.g., toothpaste) for 30 minutes after rinsing to prevent inactivation. Specifically, sodium lauryl sulfate in toothpaste can reduce efficacy. There are no known direct food interactions with chlorhexidine rinse beyond timing of use.
Avoid alcohol; high-fat meals may delay absorption but not clinically significant.
Periogard (chlorhexidine gluconate oral rinse) has not been studied in pregnant women. Animal reproduction studies have not been conducted. Based on limited systemic absorption, risk to fetus is considered low. However, due to insufficient data, use in pregnancy is generally avoided, especially during first trimester, unless clearly needed.
Acetaminophen is considered low risk in all trimesters at therapeutic doses; chronic high doses may be associated with adverse outcomes. Codeine is associated with risk of respiratory depression and neonatal withdrawal if used near term; may cause neural tube defects and other malformations with first-trimester exposure, but data are conflicting. Use lowest effective dose for shortest duration.
No data on excretion in human milk. Because chlorhexidine is poorly absorbed after oral administration, levels in breast milk are expected to be negligible. M/P ratio unknown. Use with caution in nursing mothers, but considered compatible with breastfeeding due to minimal systemic absorption.
Acetaminophen is excreted into breast milk in low amounts (M/P ratio ~0.91-1.42) and is considered compatible with breastfeeding. Codeine is also excreted in breast milk; risk of infant opioid toxicity depends on maternal CYP2D6 phenotype. Ultra-rapid metabolizers may produce higher morphine levels. Use with caution, avoid in known CYP2D6 ultra-rapid metabolizers, and monitor infant for sedation and respiratory depression.
No pharmacokinetic studies available. Due to negligible systemic absorption, dose adjustment is not anticipated in pregnancy. However, use only if clearly needed, as data are lacking.
No routine dose adjustment needed for acetaminophen. Codeine pharmacokinetics are altered in pregnancy: increased clearance and volume of distribution may require dose adjustment; however, due to variability in CYP2D6 metabolism, individualize dosing and monitor for efficacy and toxicity. Avoid codeine in pregnancy unless alternative analgesics are ineffective.
PERIOGARD (chlorhexidine gluconate 0.12%) oral rinse is used as an adjunct to periodontal treatment. It is most effective when used 30 minutes after brushing to avoid inactivation by sodium lauryl sulfate in toothpaste. Patients should be advised to avoid eating or drinking for 30 minutes after rinsing. The most common side effect is extrinsic tooth staining, which can often be removed by dental prophylaxis. Rinsing with 15 m L for 30 seconds twice daily is typical. Do not swallow; if accidental ingestion occurs, consider potential for alcohol toxicity (contains 11.6% alcohol).
For acute pain, limit codeine to 3 days; avoid in children under 12 due to CYP2D6 ultra-rapid metabolizer risk of fatal respiratory depression; monitor for constipation; assess liver function for acetaminophen hepatotoxicity; use with caution in renal impairment.
Use exactly as directed: 15 m L (1 tablespoon) for 30 seconds twice daily after brushing.,Do not swallow the rinse; spit it out after use.,Avoid eating, drinking, or rinsing with other mouthwashes for at least 30 minutes after use.,Temporary taste alteration or numbness of the tongue may occur initially.,May cause brown staining of teeth, tongue, or dental restorations; regular dental cleaning can remove stains.,Do not dilute the solution; use full strength.,If you have mouth ulcerations or oral surgery, consult your dentist before use.,Keep out of reach of children.
Take exactly as prescribed; do not exceed 4000 mg acetaminophen per day.,Avoid alcohol while taking this medication.,Do not use with other acetaminophen-containing products.,May cause dizziness or drowsiness; avoid driving until you know how you react.,Common side effects include constipation, nausea, and drowsiness.,Seek emergency if signs of allergic reaction or difficulty breathing occur.
No interactions on record
"Pirenzepine, a selective M1 muscarinic antagonist, reduces gastrointestinal motility and secretions, while codeine, an opioid agonist, also decreases gastrointestinal motility via mu-opioid receptors. Concurrent use leads to additive anticholinergic and opioid effects, resulting in enhanced risk of severe constipation, paralytic ileus, and central nervous system depression. Clinically, patients may experience exacerbated sedation, respiratory depression, and urinary retention."
"Ropinirole, a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome, may reduce the analgesic efficacy of codeine. This is likely due to pharmacodynamic antagonism at central dopamine and opioid receptors, as well as potential pharmacokinetic interactions that decrease the conversion of codeine to its active metabolite morphine via CYP2D6 inhibition by ropinirole. The resultant blunted opioid response can lead to inadequate pain control, necessitating dose adjustment or alternative therapy."
"Vemurafenib induces CYP3A4, significantly reducing the plasma concentrations of codeine, which is metabolized via CYP3A4 to its active metabolite morphine. This may diminish codeine's analgesic efficacy, potentially leading to inadequate pain control. Additionally, reduced formation of morphine may lower the risk of opioid-related adverse effects."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PERIOGARD vs ACETAMINOPHEN AND CODEINE PHOSPHATE, answered by our medical review team.
PERIOGARD is a Antiseptic mouthwash that works by Chlorhexidine gluconate is a cationic bisbiguanide that disrupts microbial cell membrane integrity, leading to leakage of intracellular contents and cell death. It exhibits broad-spectrum antimicrobial activity against gram-positive and gram-negative bacteria, fungi, and viruses.. ACETAMINOPHEN AND CODEINE PHOSPHATE is a Opioid Agonist that works by Acetaminophen: centrally acting analgesic and antipyretic, possibly via inhibition of cyclooxygenase (COX) and modulation of cannabinoid receptors. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PERIOGARD and ACETAMINOPHEN AND CODEINE PHOSPHATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PERIOGARD is: 15 m L chlorhexidine gluconate 0.12% oral rinse twice daily for 30 seconds and expectorate.. The standard adult dose of ACETAMINOPHEN AND CODEINE PHOSPHATE is: One or two tablets (acetaminophen 300 mg/codeine 30 mg per tablet) orally every 4-6 hours as needed for pain; maximum 12 tablets daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PERIOGARD and ACETAMINOPHEN AND CODEINE PHOSPHATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PERIOGARD is classified as Category C. Periogard (chlorhexidine gluconate oral rinse) has not been studied in pregnant women. Animal reproduction studies have not been conducted. Based on limited systemic absorption, ri. ACETAMINOPHEN AND CODEINE PHOSPHATE is classified as Category D/X. Acetaminophen is considered low risk in all trimesters at therapeutic doses; chronic high doses may be associated with adverse outcomes. Codeine is associated with risk of respirat. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.